分子式:C20H16N5O3F ,分子量:393.37114,Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 4.
货号 | 规格 | 数量 | 价格 |
---|---|---|---|
Q-0022315 | 100mg |
1
|
询价 |
Q-0022315 | 250mg |
1
|
询价 |
Q-0022315 | 500mg |
1
|
询价 |
Q-0022315 | 1g |
1
|
询价 |
Q-0022315 | 5g |
1
|
询价 |
参数信息 | |
---|---|
外观状态: | 固体或粉末 |
质量指标: | 95%+ |
溶解条件: | 有机溶剂/水 |
CAS号: | N/A |
分子量: | N/A |
储存条件: | -20℃避光保存 |
储存时间: | 1年 |
运输条件: | 室温2周 |
生产厂家: | 西安齐岳生物科技有限公司 |
-
32487-58-4 3-methoxyfuran-2-carbaldehyde 中间体分子
-
32487-58-4 3-methoxyfuran-2-carbaldehyde 中间体分子
-
分子式:C25H31N7O , 分子量:445.55994,Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.
-
分子式:C18H17N3O2,分子量:307.34648,纯度: > 98%,溶解性: (R.T.: 25℃): DMSO,Orteronel(TAK-700) was selected as a candidate for clinical evaluation. orteronel (TAK-700) is currently in phase III clinical trials for the treatment of castration-resistant prostate cancer.